(MYGN) Myriad Genetics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MYGN) Myriad Genetics, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Myriad Genetics, Inc. BCG Matrix is a company-specific strategic analysis that helps you see how its products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. What you see on this page is a real preview of the actual report content, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
GeneSight Psychotropic
GeneSight Psychotropic is Myriad Genetics' flagship mental-health pharmacogenomic test, and it still leads a psychotropic market that is expanding as providers try to cut trial-and-error prescribing. By late 2025, its broad brand reach and growing use support a Star profile: strong market share in a category with rising demand. It is the clearest growth engine in Myriad Genetics' portfolio.
MyChoice CDx
MyChoice CDx is Myriad Genetics, Inc.'s tumor-based HRD test for ovarian cancer treatment selection, and it fits a growing companion-diagnostic niche tied to PARP inhibitors. Roughly 50% of high-grade serous ovarian cancers show homologous recombination deficiency, which keeps demand for this assay meaningful. Myriad Genetics, Inc. has a strong clinical foothold here, so MyChoice CDx supports Star status in the BCG Matrix.
Prequel Prenatal Screen
Prequel Prenatal Screen is Myriad Genetics, Inc.'s non-invasive prenatal screening test that uses maternal blood, and it fits a high-growth niche as prenatal testing volumes rise and panels widen. In FY2025, Myriad Genetics kept prenatal genetics in focus while the U.S. still saw about 3.6 million births a year, supporting a large addressable market. If Prequel keeps taking share, it has Star status in the BCG Matrix.
Foresight Carrier Screen
Foresight Carrier Screen fits the Star bucket because it serves carrier screening in reproductive health, where preconception and prenatal testing demand keeps broadening. If Myriad Genetics, Inc. holds strong share as the market expands, the franchise can keep scaling with it.
In Myriad Genetics, Inc.'s 2025 to 2026 mix, this is the kind of asset that can support growth if volume rises faster than pricing pressure. One line: growth in reproductive testing is the key.
- Carrier screening demand is expanding
- Preconception and prenatal use cases grow
- Star status depends on sustained share
Precise Tumor
Precise Tumor fits Myriad Genetics, Inc.’s broader personalized oncology push, and precision oncology is still a fast-growing diagnostics niche. Myriad reported FY2025 revenue of about $840 million, with oncology assets central to its growth plan, which supports the Star case. The category keeps expanding as more cancers are matched to biomarker-driven testing and treatment.
- High-growth oncology diagnostics
- Backed by Myriad FY2025 investment
- Star potential, but execution matters
Myriad’s Star Tests Still Drive Growth
Myriad Genetics, Inc. stars are GeneSight, MyChoice CDx, Prequel, and Foresight, because each sits in a growing test market and still holds clear share. FY2025 revenue was about $840 million, so these franchises matter to the top line. One line: growth still comes from volume, not price.
| Asset | Star signal | FY2025 data |
|---|---|---|
| GeneSight | Mental-health PGx leader | Flagship growth driver |
| Prequel | Prenatal testing growth | U.S. births ~3.6M |
| MyChoice CDx | HRD oncology niche | ~50% HGSOC HRD rate |
What is included in the product
Detailed Word Document
Myriad Genetics BCG Matrix: quadrant-by-quadrant view of growth, cash, and divestment priorities.
Editable Excel File
Quick BCG snapshot for Myriad Genetics, Inc. to spot growth, cash, and drag at a glance.
Reference Sources
Provides a clear source trail for Myriad Genetics data, boosting credibility and speeding investor due diligence.
Cash Cows
MyRisk Hereditary Cancer Test
MyRisk Hereditary Cancer Test is one of Myriad Genetics, Inc.'s core hereditary cancer panels, and it sits in a more mature market than newer oncology or prenatal lines. Its strong brand and installed base help it act as a cash generator for the portfolio.
In FY2025, Myriad Genetics, Inc. still leaned on hereditary cancer testing as a key revenue driver, even as it pushed newer products. That steadier demand makes MyRisk less of a growth story and more of a funding engine.
For a BCG Matrix view, MyRisk fits the Cash Cow box: high share in a slow-growing category, with recurring test demand and proven clinical use supporting margins.
BRACAnalysis CDx
BRACAnalysis CDx is Myriad Genetics' FDA-cleared companion diagnostic for BRCA1/2 variants, tied to PARP inhibitor and other oncology decisions. It sits in a mature testing lane, so growth is modest, but the 2-gene franchise still throws off steady cash because it is embedded in routine hereditary cancer workflows and remains clinically relevant.
Prolaris Prostate Cancer Prognostic Test
Prolaris is a clinically established prostate cancer prognostic test, and that fits a cash cow profile in Myriad Genetics, Inc.’s BCG mix. The U.S. still expects about 313,780 new prostate cancer cases in 2025, but the risk-testing space is mature, so growth is steadier than explosive. That means Prolaris can keep generating cash through an entrenched clinical role, even if it is not the main growth engine.
EndoPredict Breast Cancer Prognostic Test
EndoPredict Breast Cancer Prognostic Test fits the Cash Cows bucket because it is a mature, clinically established assay that helps Myriad Genetics, Inc. generate steady revenue rather than chase fast new growth. In a proven breast cancer prognostic market, demand is tied to routine treatment decisions, so cash flow is more stable than in newer precision-oncology products.
Myriad Genetics, Inc. uses EndoPredict to defend share in a well-known category, where payor coverage and clinician adoption matter more than breakout expansion. The test’s role is clear: support recurring sales and margin discipline, not a heavy reinvestment cycle.
- Stable, mature breast cancer assay
- Supports recurring cash flow
- Lower growth, lower reinvestment need
- Fits Cash Cows in BCG Matrix
Hereditary Cancer Reporting Base
Myriad Genetics, Inc.'s hereditary cancer reporting base is a cash cow because the interpretation and reporting system already supports a mature menu, including MyRisk with 48 genes and BRACAnalysis. The clinical installed base is deep, so new reports add revenue with limited launch cost. In FY2024, Myriad generated about $800 million in revenue, and this base helps defend that recurring stream.
- 48-gene hereditary cancer menu
- Mature installed clinical base
- Low incremental launch cost
Myriad’s Cash Cows Keep Revenue Steady in FY2025
Myriad Genetics, Inc.'s Cash Cows are the mature hereditary cancer assets, led by MyRisk and BRACAnalysis CDx. In FY2025, hereditary cancer testing still anchored revenue while newer lines grew slower, so these products acted as steady cash generators, not growth drivers. Their value comes from entrenched clinical use, repeat demand, and low reinvestment needs.
| Asset | BCG role | FY2025 signal |
|---|---|---|
| MyRisk | Cash Cow | Core hereditary cancer revenue |
| BRACAnalysis CDx | Cash Cow | Stable companion diagnostic demand |
Get Your Copy
Myriad Genetics, Inc. Reference Sources
The Myriad Genetics, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages or placeholder content—just the full, ready-to-use file. It’s formatted for clear strategic analysis and immediate professional use.
Dogs
Legacy Single-Gene BRCA Testing
Legacy Single-Gene BRCA Testing is a Dog for Myriad Genetics, Inc.: it covers just 2 genes, while MyRisk panels cover up to 48 genes, so demand keeps shifting to broader hereditary cancer testing. That leaves BRCA-only volume with low growth and low strategic value. The category is now more of a tail product than a growth driver.
Low-Volume Custom Molecular Testing
Low-volume custom molecular testing sits in the "Dogs" box because it is not a scale driver and usually lacks clear differentiation. In FY2025, Myriad Genetics generated about $0.84B in revenue, so small one-off work can still tie up high-value lab capacity without moving the needle much. If these services do not earn premium margins or repeat volume, they can turn into a cash trap.
Small Non-Core International Services
Myriad Genetics, Inc. still earns most of its value from core U.S. brands, while small non-core international services stay niche and face tougher reimbursement and lower share. That mix fits the Dog bucket: weak relative position, limited scale, and little pricing power. Unless Myriad can lift reimbursement or expand volume, these businesses are likely cash traps, not growth engines.
Mature Standalone Add-On Panels
Myriad Genetics, Inc.'s mature standalone add-on panels fit the Dogs box: small panels are easy to copy, and larger rivals can bundle broader menus at lower cost. In a low-growth market, Myriad Genetics, Inc. also lacks the share needed to win on price or scale, so these panels tend to trap capital with weak upside.
- Small panels commoditize fast
- Big rivals bundle cheaper
- Low growth, low share
Discontinued Legacy Assays
Discontinued legacy assays sit in the Dogs box because they no longer drive growth and now live mostly as a small installed-base tail. Myriad Genetics, Inc. has shifted capital toward newer, higher-demand tests, so these older assays add little to 2026 revenue momentum and usually carry only limited renewal volume.
- Low growth, low strategic priority
- Mostly installed-base revenue
- Capital moves to newer assays
Tail Products Weigh on Myriad’s Growth
Dogs at Myriad Genetics, Inc. are legacy BRCA-only, small add-on, and low-volume custom assays: they have weak growth, low share, and little pricing power. FY2025 revenue was about $0.84B, but these tail products do not drive the mix shift toward higher-value panels. They mostly use capacity without adding much scale.
| Dog segment | Why it fits |
|---|---|
| Legacy BRCA-only | 2 genes vs up to 48 |
Question Marks
Precise Tumor Expansion
Myriad Genetics, Inc. launched Precise Tumor after its core hereditary and prenatal franchises, so it is still a newer, smaller 2025 growth driver. The tumor-profiling market is still expanding, but it is crowded, with heavy competition from Foundation Medicine and Guardant Health. Precise Tumor needs clear share gains and faster adoption to move out of Question Mark status.
Intermountain Precision Genomics Alliance
Intermountain Precision Genomics Alliance helps Myriad Genetics expand germline and somatic tumor testing inside a care network that faces about 2.0 million new U.S. cancer cases in 2025. That gives Myriad a faster path into oncology workflows, but the alliance is still a Question Mark until it proves real share and repeat test volume.
Partnership-led access can speed adoption, yet Myriad still has to convert that reach into durable revenue and margin gain.
Expanded Somatic Tumor Testing
Expanded somatic tumor testing sits in a fast-growing space, since solid tumors account for roughly 90% of cancer cases. Myriad Genetics, Inc. has room to win share, but the market is crowded with large labs and specialty rivals, so growth will likely need heavier spend on assay breadth, reimbursement, and sales reach. It can become a Star only if that investment lifts volume faster than rivals.
New Prenatal Add-Ons
New Prenatal Add-Ons fit the Question Mark spot: prenatal genetics keeps adding markers and workflow steps, but Myriad Genetics, Inc. still needs payer wins and clinician uptake to scale share. In BCG terms, the category has growth potential, yet demand can stay uneven until coverage becomes routine. The key test is whether add-on tests move from niche use to standard prenatal panels.
- High growth, low share today
- Payer coverage is the swing factor
- Adoption speed decides future share
International Rollouts
Outside the U.S., Myriad Genetics, Inc. faces local rivals and patchy reimbursement, so rollout speed stays uneven. That keeps International Rollouts in Question Mark territory: the addressable market in oncology and reproductive health is real, but current share is still low. The next step is proving payer access country by country.
- Local competitors दब crowd the market.
- Reimbursement varies by country.
- Oncology and reproductive health still offer upside.
- Low share keeps returns uncertain.
Myriad’s Question Marks: High Growth, Low Share, 2025 Will Decide
Question Marks at Myriad Genetics, Inc. are newer oncology and prenatal bets with high growth but low share. Precise Tumor, Intermountain Precision Genomics Alliance, and international rollouts can grow fast, but 2025 adoption, payer access, and repeat volume still decide if they scale or stay niche.
| Area | 2025 signal |
|---|---|
| Precise Tumor | Crowded market |
| Oncology access | About 2.0M U.S. cancer cases |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.